Tredan O, Corset V, Wang Q, et al. Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study. J Clin Oncol. 35, 2017 (suppl; abstr LBA100).
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker